Kristin Stafford - 06 Apr 2026 Form 4 Insider Report for Zymeworks Inc. (ZYME)

Reporting relationship: EVP, Chief Financial Officer
Issuer ticker: ZYME
Reported as of: 06 Apr 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 07 Apr 2026, 14:24:31 UTC
Prior SEC filing: 07 Apr 2026
Next SEC filing: 03 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Catherine Graham, Attorney-in-Fact

Key filing fact

Kristin Stafford filed Form 4 for Zymeworks Inc. (ZYME) on 07 Apr 2026.

Key facts

This page summarizes Kristin Stafford's Form 4 filing for Zymeworks Inc. (ZYME).
3 reported transactions and 3 derivative rows are listed below.
Accepted by SEC: 07 Apr 2026, 14:24.

Change

Previous filing in this sequence was filed on 07 Apr 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001970438 Primary reporting owner

Stafford Kristin

Relationship: EVP, Chief Financial Officer
Address: C/O ZYMEWORKS INC., 108 PATRIOT DRIVE, SUITE A, MIDDLETOWN
Signature: /s/ Catherine Graham, Attorney-in-Fact
Signature date: 07 Apr 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ZYME transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +178,000
Change %
Price: $0.000000^*
Shares after: 178,000
Date: 06 Apr 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 178,000
Exercise price: $25.84
Footnotes: F1

ZYME transaction Derivative

Restricted Stock Unit

Award

Transaction value
Shares: +119,000
Change %
Price: $0.000000^*
Shares after: 119,000
Date: 06 Apr 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 119,000
Exercise price
Footnotes: F2, F3

ZYME transaction Derivative

Restricted Stock Unit

Award

Transaction value
Shares: +50,000
Change %
Price: $0.000000^*
Shares after: 50,000
Date: 06 Apr 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 50,000
Exercise price
Footnotes: F2, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

Stock options vest as follows: (i) 25% of underlying shares of common stock on first anniversary of grant date and (ii) remainder of underlying shares of common stock in 36 equal monthly installments on last day of month following first anniversary of grant date.

Footnote F2

Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock.

Footnote F3

RSUs vest in four equal annual installments beginning on first anniversary of grant date.

Footnote F4

RSUs vest in three equal annual installments beginning on first anniversary of grant date.